Company overview
SomaLogic offers the SomaScan Assay, a high-plex proteomics platform measuring over 7,000 proteins simultaneously from small plasma or serum samples with high sensitivity, specificity, and reproducibility. It supports biomarker discovery, drug development, diagnostics, and clinical testing for cardiovascular risk, cancer, and other diseases. Now part of Illumina, it enables multiomics insights for pharmaceutical R&D and health management.
SomaLogic is listed in the NovaPharmaNews Supplier Hub as a Life Science Reagents, Diagnostics & Testing partner serving United States & Americas. Core focus areas include somalogic, somascan assay, proteomics platform, biomarker discovery, protein measurement.
Industry categories: Life Science Reagents, Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with SomaLogic include Assay — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://somalogic.com
- Categories
- Life Science Reagents, Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- somalogic, somascan assay, proteomics platform, biomarker discovery, protein measurement
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What proteomics capabilities does SomaLogic provide?
- The SomaScan Assay measures over 7,000 proteins from 55-µl plasma/serum samples, offering high-plex, high-throughput analysis for biomarker discovery, drug development, and clinical testing across species and sample types.
- What are SomaLogic's clinical offerings?
- SomaSignal Tests use protein patterns from blood to predict health states and disease risks, such as 4-year cardiovascular event likelihood, validated in diverse global populations.
- How does SomaLogic support pharma R&D?
- Curated SomaScan Panels target proteins for drug discovery/development, cancer proteomics covering half the proteome, and integration with Illumina for multiomics biomarker and disease profiling.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
